{ "model": { "rank": 4154, "code": "thing-q1485", "model_id": "vr.tr.systemic-lupus-erythematosus", "name": "systemic lupus erythematosus", "purpose": "Enable an AI agent to recognise a documented systemic lupus erythematosus presentation, assess its evolving activity and consequences, and support clinician-directed monitoring and care decisions.", "family": "Thing Registry", "category": "Information and virtual systems", "status": "research-draft", "kind": "thing", "plane": "INF", "domain": "INF.KNW", "industry": "", "version": "", "url": "/models/thing/q1485/", "tier": 2, "score": 78, "payload": { "layer": "wikidata", "aliases": [ "pediatric systemic lupus erythematosus", "Lupus vasculitis", "systemic lupus erythematosus and pregnancy", "neuropsychiatric systemic lupus erythematosus" ], "aliasCount": 4, "merged": 4, "knownIn": 78, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": null, "source": { "dataset": "wikidata", "item": "Q1485", "url": "https://www.wikidata.org/wiki/Q1485", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-09T19:36:02Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 26, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a087aa-48ce-7262-8f05-3e6347747bea\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: systemic lupus erythematosus\nSense to describe: (none recorded)\nDomain code: XCT.STA\nAlso known as: (none)\n\n\nContext for this batch of 695 things:\n# Bat", "usd": 0, "recall": true }, "codex": { "seconds": 83.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a087aa-48be-7762-9856-70cb4ca50b24\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: systemic lupus erythematosus\nRegistry id: vr.tr.systemic-lupus-erythematosus\nPlane / domain: XCT / XCT.STA\nRegistry definition: (none recorded)\nNames" } } }, "metaModel": { "id": "THING-Q1485", "registryId": "vr.tr.systemic-lupus-erythematosus", "name": "systemic lupus erythematosus", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "XCT.STA" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q1485/", "model": { "registry_id": "vr.tr.systemic-lupus-erythematosus", "name": "systemic lupus erythematosus", "purpose": "Enable an AI agent to recognise a documented systemic lupus erythematosus presentation, assess its evolving activity and consequences, and support clinician-directed monitoring and care decisions.", "definition": "Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by loss of tolerance to self-antigens, autoantibody production, and variable inflammatory injury affecting multiple organs, often with a relapsing-remitting course.", "scope_statement": "This model owns systemic lupus erythematosus (SLE), registry entry vr.tr.systemic-lupus-erythematosus in XCT / XCT.STA, as a chronic autoimmune disease with potentially multisystem involvement, including diagnostic uncertainty, manifestation attribution, longitudinal state and care constraints. [NIAMS overview](https://www.niams.nih.gov/health-topics/lupus)", "in_scope": [ "Evidence supporting or challenging an SLE diagnosis and its distinction from research classification", "Organ-specific manifestations and the evidence attributing them to SLE", "Disease activity, flares, remission, accumulated damage and patient-experienced burden", "Autoantibody, complement, blood, urine and tissue findings interpreted in clinical context", "Treatment objectives, observed response, adverse effects and monitoring dependencies", "SLE-specific reproductive, thrombotic, infection and cardiovascular risk interfaces" ], "out_of_scope": [ "Independent models of isolated cutaneous lupus, drug-induced lupus and neonatal lupus", "Full definitions and management of antiphospholipid syndrome or other overlapping autoimmune diseases", "Complete nephrology models of kidney pathology, chronic kidney disease and renal replacement therapy", "Drug manufacture, pharmacology and prescribing protocols as independent subjects", "General pregnancy management and comprehensive models of infection or cardiovascular disease" ], "distinguishing_features": [ "Require a coherent clinical history, examination and supporting investigations; a positive antinuclear antibody result alone does not establish SLE. [NIAMS diagnosis](https://www.niams.nih.gov/health-topics/lupus/diagnosis-treatment-and-steps-to-take)", "Distinguish SLE from isolated cutaneous lupus by recording the full clinical and immunological assessment; a skin lesion alone does not determine the systemic diagnosis.", "Examine medication exposure, symptom chronology and clinician attribution when distinguishing SLE from drug-induced lupus.", "Distinguish a suspected lupus flare from infection, treatment toxicity and established damage by retaining competing explanations for each new abnormality.", "Record antiphospholipid antibodies and thrombotic or obstetric events separately from the SLE diagnosis, allowing an independently assessed antiphospholipid syndrome relationship." ], "characteristics": [ { "name": "Diagnostic standing", "kind": "state", "unit_or_values": "Suspected, clinician-established, under reassessment or excluded; assessor and date required", "why_it_matters": "Prevents a screening result or provisional label from becoming an unquestioned diagnosis." }, { "name": "Classification assessment", "kind": "category", "unit_or_values": "Named criteria set and version; met, not met or insufficient information", "why_it_matters": "Keeps research classification distinct from clinical diagnostic judgment." }, { "name": "Manifestation attribution", "kind": "relation", "unit_or_values": "Manifestation linked to SLE, another cause, multiple causes or unresolved attribution, with evidence", "why_it_matters": "A new symptom in someone with SLE need not be caused by SLE." }, { "name": "Organ involvement", "kind": "category", "unit_or_values": "Mucocutaneous, musculoskeletal, renal, hematologic, neuropsychiatric, cardiopulmonary or other specified involvement", "why_it_matters": "The affected organ and severity determine the care pathway." }, { "name": "Autoantibody profile", "kind": "measurement", "unit_or_values": "Antibody specificity, result, assay, laboratory reference range and collection date; ANA titre and pattern where reported", "why_it_matters": "Makes supporting evidence comparable without treating different assays as interchangeable." }, { "name": "Complement profile", "kind": "measurement", "unit_or_values": "C3 and C4 in laboratory-reported units with reference intervals and longitudinal trend", "why_it_matters": "Preserves a potentially relevant activity signal without equating it with clinical activity." }, { "name": "Renal surveillance", "kind": "measurement", "unit_or_values": "Creatinine, eGFR, urine protein quantification and urine sediment, each with units, method and date", "why_it_matters": "Supports detection and follow-up of possible renal involvement." }, { "name": "Disease activity", "kind": "measurement", "unit_or_values": "Named instrument such as SLEDAI-2K or BILAG-2004, version, score or grades, assessment window and missing items", "why_it_matters": "Allows longitudinal assessment while preserving the meaning and limits of the instrument used." }, { "name": "Clinical course", "kind": "state", "unit_or_values": "Active, improving, stable, suspected flare, defined low disease activity or defined remission", "why_it_matters": "Records change over time and requires explicit definitions for treatment targets." }, { "name": "Accumulated damage", "kind": "measurement", "unit_or_values": "Named damage instrument and item-level findings, onset, persistence and attributed causes", "why_it_matters": "Separates persistent consequences from potentially reversible inflammation." }, { "name": "Treatment exposure", "kind": "relation", "unit_or_values": "Therapy linked to indication, dose, dates, actual use, response and adverse events", "why_it_matters": "Makes response and toxicity interpretable against what the person actually received." }, { "name": "Patient-experienced burden", "kind": "measurement", "unit_or_values": "Fatigue, pain, function and quality-of-life measures with instrument, scale and date", "why_it_matters": "Captures consequences that clinician-assessed inflammatory activity may not explain." } ], "affordances": [ "Assemble a dated diagnostic evidence summary with conflicting findings and missing investigations.", "Compare successive assessments to flag possible flare, organ involvement or treatment complications for clinical review.", "Track clinician-selected activity and damage measures without silently substituting one instrument for another.", "Construct a monitoring checklist tied to documented manifestations, therapies and the applicable guideline version.", "Summarise treatment response, patient priorities and unresolved trade-offs for shared decisions.", "Route concerning changes through an established escalation pathway while preserving diagnostic uncertainty." ] }, "sources": [], "structure": { "bundles": [ { "id": "sle-identity-and-evidence", "name": "SLE identity and diagnostic evidence", "description": "Establish what supports this SLE label and how competing explanations were evaluated.", "rationale": "An agent must distinguish an established diagnosis from seropositivity, a classification result or an unresolved lupus-like presentation.", "layers": [ { "id": "clinical-diagnosis-and-classification", "name": "Clinical diagnosis and classification", "description": "Maintain separate records of clinical judgment and criteria-based classification.", "findings": [ { "id": "diagnostic-basis", "name": "Diagnostic basis", "description": "Record the diagnosing clinician, chronology, supporting manifestations, investigations and any separately applied classification framework.", "questions": [ { "text": "Who established or questioned the SLE diagnosis, when, and on what clinical evidence?", "kind": "provenance", "id": "diagnostic-basis-q01" }, { "text": "Which classification framework, if any, was applied, and which observations supported or failed its requirements?", "kind": "definition", "id": "diagnostic-basis-q02" } ] } ] }, { "id": "lupus-boundaries-and-mimics", "name": "Lupus boundaries and mimics", "description": "Record alternatives including isolated cutaneous lupus, drug-induced lupus and overlapping connective tissue disease.", "findings": [ { "id": "alternative-explanations", "name": "Alternative explanations", "description": "Represent each competing diagnosis with supporting evidence, contradictory evidence and unresolved distinctions.", "questions": [ { "text": "What evidence distinguishes this presentation from isolated cutaneous lupus, drug-induced lupus or another connective tissue disease?", "kind": "boundary", "id": "alternative-explanations-q01" }, { "text": "Which medication exposures, infection findings or other conditions could explain the apparent lupus manifestations?", "kind": "provenance", "id": "alternative-explanations-q02" } ] } ] } ] }, { "id": "immune-and-laboratory-context", "name": "Immune and laboratory context", "description": "Interpret immunological evidence and laboratory trends in relation to clinical observations.", "rationale": "Lupus assessment uses multiple tests whose meaning depends on assay, timing and accompanying manifestations.", "layers": [ { "id": "autoantibody-evidence", "name": "Autoantibody evidence", "description": "Preserve antibody specificity and analytical context.", "findings": [ { "id": "serological-profile", "name": "Serological profile", "description": "Record ANA, anti-dsDNA, anti-Sm and other relevant antibodies without treating an individual result as a complete diagnosis.", "questions": [ { "text": "Which antibodies were measured, using which methods, and what were the results and laboratory reference limits?", "kind": "measurement", "id": "serological-profile-q01" }, { "text": "Which results support the clinician's SLE assessment, and which instead inform an overlap diagnosis or a specific risk?", "kind": "boundary", "id": "serological-profile-q02" } ] } ] }, { "id": "laboratory-clinical-concordance", "name": "Laboratory and clinical concordance", "description": "Compare serial laboratory changes with symptoms, examination and treatment exposure.", "findings": [ { "id": "discordant-activity-signals", "name": "Discordant activity signals", "description": "Retain disagreement between serological trends and clinical activity as an unresolved assessment issue.", "questions": [ { "text": "How have complement, anti-dsDNA and blood counts changed relative to the person's baseline and clinical course?", "kind": "measurement", "id": "discordant-activity-signals-q01" }, { "text": "When laboratory and clinical findings disagree, what explanation and follow-up plan has the clinician documented?", "kind": "action", "id": "discordant-activity-signals-q02" } ] } ] } ] }, { "id": "organ-involvement-and-attribution", "name": "Organ involvement and attribution", "description": "Describe where SLE may be active and how confidently manifestations are attributed to it.", "rationale": "A global lupus label cannot convey the significance of renal changes, inflammatory joint symptoms or potentially urgent organ dysfunction.", "layers": [ { "id": "renal-involvement", "name": "Renal involvement", "description": "Track evidence of possible lupus nephritis and link to specialist renal assessment.", "findings": [ { "id": "renal-evidence-and-pathology", "name": "Renal evidence and pathology", "description": "Connect urine findings, kidney function and any biopsy interpretation while preserving alternative renal causes.", "questions": [ { "text": "What do serial urine protein measurements, urine sediment and kidney function show, and over what interval?", "kind": "measurement", "id": "renal-evidence-and-pathology-q01" }, { "text": "If a kidney biopsy was performed, what did the report establish about classification, activity, chronicity and competing pathology?", "kind": "provenance", "id": "renal-evidence-and-pathology-q02" } ] } ] }, { "id": "extrarenal-manifestations", "name": "Extrarenal manifestations", "description": "Record attributed skin, joint, blood, nervous system, heart and lung findings individually.", "findings": [ { "id": "manifestation-severity-and-cause", "name": "Manifestation severity and cause", "description": "For each manifestation, retain onset, objective evidence, functional effect, severity and possible non-lupus causes.", "questions": [ { "text": "Which extrarenal findings are present, how severe are they, and what evidence attributes each to SLE?", "kind": "measurement", "id": "manifestation-severity-and-cause-q01" }, { "text": "Which findings require prompt clinical assessment under the applicable pathway, and who owns that escalation?", "kind": "action", "id": "manifestation-severity-and-cause-q02" } ] } ] } ] }, { "id": "activity-damage-and-lived-course", "name": "Activity, damage and lived course", "description": "Separate current inflammation, persistent consequences and the person's experienced burden.", "rationale": "These dimensions can diverge and support different interpretations of whether care is succeeding.", "layers": [ { "id": "activity-and-treatment-targets", "name": "Activity and treatment targets", "description": "Record disease trajectory using explicit assessment windows and target definitions.", "findings": [ { "id": "flare-and-target-assessment", "name": "Flare and target assessment", "description": "Document the evidence for a flare and the exact framework used to describe remission or low disease activity.", "questions": [ { "text": "Which new or worsening findings support a flare compared with the previous assessment, and what alternatives remain?", "kind": "boundary", "id": "flare-and-target-assessment-q01" }, { "text": "What definition, instrument and observation window support the recorded activity state or treatment target?", "kind": "definition", "id": "flare-and-target-assessment-q02" } ] } ] }, { "id": "damage-and-patient-burden", "name": "Damage and patient burden", "description": "Keep persistent organ consequences and patient-reported outcomes visible alongside activity scores.", "findings": [ { "id": "persistent-consequences", "name": "Persistent consequences", "description": "Record damage and limitations without assuming that every persistent symptom represents active lupus.", "questions": [ { "text": "Which persistent changes meet the selected damage definition, and are they attributed to SLE, treatment or another cause?", "kind": "boundary", "id": "persistent-consequences-q01" }, { "text": "How are fatigue, pain and daily function changing, and where do they diverge from assessed inflammatory activity?", "kind": "measurement", "id": "persistent-consequences-q02" } ] } ] } ] }, { "id": "therapy-response-and-monitoring", "name": "Therapy, response and monitoring", "description": "Link treatment decisions to manifestations, measurable goals, actual exposure and safety monitoring.", "rationale": "An agent needs enough context to support a documented care plan and identify gaps without deriving prescriptions from a disease label.", "layers": [ { "id": "treatment-purpose-and-response", "name": "Treatment purpose and response", "description": "Represent the rationale and observed results of each therapy within a versioned clinical plan.", "findings": [ { "id": "manifestation-linked-treatment", "name": "Manifestation-linked treatment", "description": "Record the target manifestation, intended outcome, review interval and clinician-approved plan; relevant guidance includes the [2025 ACR SLE guideline](https://doi.org/10.1002/acr.25690).", "questions": [ { "text": "Which manifestations and patient priorities does each therapy address, and how will benefit be assessed?", "kind": "action", "id": "manifestation-linked-treatment-q01" }, { "text": "What treatment was actually taken, and how did clinical findings change after initiation, adjustment or interruption?", "kind": "provenance", "id": "manifestation-linked-treatment-q02" } ] } ] }, { "id": "exposure-and-toxicity", "name": "Exposure and toxicity", "description": "Track lupus treatment exposure together with medication-specific monitoring requirements.", "findings": [ { "id": "treatment-monitoring-dependencies", "name": "Treatment monitoring dependencies", "description": "Capture glucocorticoid exposure, hydroxychloroquine eye-monitoring arrangements where applicable, and relevant surveillance for other therapies.", "questions": [ { "text": "What cumulative exposure, suspected toxicity or monitoring gap could affect the documented treatment plan?", "kind": "measurement", "id": "treatment-monitoring-dependencies-q01" }, { "text": "Which monitoring or medication-review actions are due, according to the responsible clinician's plan and cited guidance?", "kind": "action", "id": "treatment-monitoring-dependencies-q02" } ] } ] } ] }, { "id": "reproductive-and-comorbidity-interfaces", "name": "Reproductive and comorbidity interfaces", "description": "Connect SLE to risk assessments that require coordinated care across neighbouring models.", "rationale": "Pregnancy, thrombosis, infection and cardiovascular disease introduce decisions that disease activity alone cannot resolve.", "layers": [ { "id": "reproductive-and-antibody-context", "name": "Reproductive and antibody context", "description": "Record reproductive intentions and relevant clinical and antibody findings without inferring pregnancy or reproductive capacity.", "findings": [ { "id": "pregnancy-and-thrombosis-links", "name": "Pregnancy and thrombosis links", "description": "Link pregnancy planning or pregnancy to disease state, medication review and relevant antibody findings; preserve separate assessment of antiphospholipid syndrome. [NIAMS pregnancy considerations](https://www.niams.nih.gov/health-topics/lupus/diagnosis-treatment-and-steps-to-take)", "questions": [ { "text": "If reproductive care is relevant, what disease activity, renal history, antibody results and medication exposures must the care team review?", "kind": "action", "id": "pregnancy-and-thrombosis-links-q01" }, { "text": "Are antiphospholipid antibodies, thrombotic events or obstetric complications documented, and has antiphospholipid syndrome been independently assessed?", "kind": "boundary", "id": "pregnancy-and-thrombosis-links-q02" } ] } ] }, { "id": "infection-and-cardiovascular-context", "name": "Infection and cardiovascular context", "description": "Connect intercurrent illness and preventive care to SLE activity and treatment exposure.", "findings": [ { "id": "competing-risks-and-prevention", "name": "Competing risks and prevention", "description": "Preserve infection as a competing explanation for deterioration and record coordinated preventive care responsibilities.", "questions": [ { "text": "For a new deterioration, what evidence supports infection, lupus activity, treatment toxicity or more than one cause?", "kind": "boundary", "id": "competing-risks-and-prevention-q01" }, { "text": "What infection-prevention and cardiovascular-risk actions are documented, and who is responsible for follow-up?", "kind": "action", "id": "competing-risks-and-prevention-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Age thresholds for childhood-onset and late-onset SLE vary between studies, and these are descriptive groupings rather than universally standardized subtypes.", "Verify current guideline versions and local coding details; no single laboratory result establishes or excludes SLE." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Childhood-onset SLE", "Adult-onset SLE", "Late-onset SLE" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "ICD-10, World Health Organization", "value_or_pattern": "M32", "note": "Systemic lupus erythematosus category; subcodes distinguish forms and involvement, with national coding modifications." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "2019 EULAR/ACR classification criteria, issued by the European Alliance of Associations for Rheumatology and American College of Rheumatology; classification criteria support research cohort definition and are not diagnostic rules.", "2012 SLICC classification criteria, developed by the Systemic Lupus International Collaborating Clinics.", "2023 EULAR recommendations for the management of systemic lupus erythematosus.", "KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Clinical recognition and longitudinal management of multisystem autoimmune disease.", "Classification of participants for clinical trials and observational research.", "Monitoring disease activity, accumulated organ damage, and treatment response.", "Assessment of pregnancy-related risks and coordination of specialist care.", "Health surveillance and administrative coding." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Disease activity assessed using SLEDAI-2K", "typical_range": "Possible score 0-105; this is the instrument range, not a typical patient range.", "unit": "score points" }, { "quantity": "Serum complement C3 and C4 concentrations", "typical_range": "Laboratory-dependent; reduced concentrations may accompany active disease.", "unit": "g/L or mg/dL" }, { "quantity": "Urinary protein excretion", "typical_range": "Variable; increased excretion can indicate renal involvement and requires contextual interpretation.", "unit": "g/24 h" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Lupus nephritis can cause irreversible kidney damage and kidney failure.", "Neurological, cardiac, pulmonary, and hematological involvement can be organ-threatening or life-threatening.", "Infection can mimic a flare and can be worsened by immunosuppressive treatment.", "Accelerated cardiovascular disease and thrombosis, particularly with associated antiphospholipid syndrome, contribute to morbidity.", "Misinterpreting isolated autoantibody positivity or research classification criteria as sufficient for diagnosis can cause misdiagnosis." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Reported prevalence, severity, and organ involvement vary across populations; ancestry, environment, ascertainment, and access to care all contribute.", "Access to rheumatology, laboratory monitoring, kidney biopsy, and treatment affects recognition and outcomes.", "ICD subcodes and treatment availability differ across national health systems." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Cutaneous lupus erythematosus", "difference": "Primarily denotes lupus affecting the skin; it may occur independently or as part of SLE, so skin lesions alone do not establish systemic disease." }, { "name": "Drug-induced lupus", "difference": "A lupus-like syndrome associated with a causative medication, typically improving after withdrawal; clinical and antibody patterns depend on the drug." }, { "name": "Lupus nephritis", "difference": "Renal involvement associated with SLE, rather than a synonym for the entire systemic disease." }, { "name": "Antiphospholipid syndrome", "difference": "Defined around characteristic thrombotic or obstetric manifestations and persistent antiphospholipid antibodies; it can occur independently or alongside SLE." }, { "name": "Neonatal lupus", "difference": "Results from transferred maternal autoantibodies and is not equivalent to childhood-onset SLE." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of systemic lupus erythematosus this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which diagnostic and classification frameworks should the completed model support across adult, childhood-onset and incomplete lupus presentations?", "Which activity, remission, low disease activity and damage definitions should be adopted, and how should assessments using different instruments remain comparable?", "What evidence should be required to attribute neuropsychiatric symptoms, fatigue or persistent pain to SLE when competing explanations remain plausible?", "Which assay-specific trends and combinations of observations justify a review alert, particularly when serological activity and clinical findings disagree?", "How should the completed model divide responsibility with lupus nephritis, antiphospholipid syndrome and reproductive-care models while retaining a coherent SLE assessment?" ], "statistics": { "bundles": 7, "layers": 13, "findings": 21, "questions": 33 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "discipline or field of knowledge", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a systemic lupus erythematosus, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise a documented systemic lupus erythematosus presentation, assess its evolving activity and consequences, and support clinician-directed monitoring and care decisions.", "characteristics": { "substance": "information", "origin": "conceptual", "agency": "inert" }, "whatYouCanDoWithIt": [ "read and interpreted" ], "distinguishingFeatures": [ "Names folded into this entry, which a task may need to split apart again: pediatric systemic lupus erythematosus, Lupus vasculitis, systemic lupus erythematosus and pregnancy, neuropsychiatric systemic lupus erythematosus.", "4 finer distinctions are held as aliases rather than separate entries, because telling them apart needs a task that asks for it.", "Described in 78 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a systemic lupus erythematosus, and on what evidence are they told apart?" ], "whatItIsMadeOf": "content that has to be carried by something else", "physicalCharacter": [ "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "read it and act on what it says" ], "howItIsRecognised": [], "relatedModels": [ { "relation": "covers", "note": "Finer kinds folded into this entry because telling them apart needs a task that asks for it. Each is a model waiting to be split out when one does.", "targets": [ "pediatric systemic lupus erythematosus", "Lupus vasculitis", "systemic lupus erythematosus and pregnancy", "neuropsychiatric systemic lupus erythematosus" ] } ], "standing": "Described in 78 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is. 4 finer distinctions are held inside this entry as names rather than as separate models.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one systemic lupus erythematosus from another, and a systemic lupus erythematosus from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a systemic lupus erythematosus sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a systemic lupus erythematosus from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a systemic lupus erythematosus passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a systemic lupus erythematosus between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a systemic lupus erythematosus, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a systemic lupus erythematosus is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "content-and-access", "name": "Content, encoding and access", "description": "What a systemic lupus erythematosus says, how it is encoded and who may read it.", "rationale": "An informational thing carries content that can be copied, versioned and withheld, none of which its physical carrier explains.", "layers": [ { "id": "content-and-encoding", "name": "Content and encoding", "description": "The content itself, its format and its language.", "findings": [ { "id": "content-and-format", "name": "Content, format and language", "description": "What a systemic lupus erythematosus contains and in what form it is held.", "questions": [ { "id": "content-and-format-q01", "text": "What identifies and describes the content of a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "content-and-format-q02", "text": "Who or what asserted this about the content of a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "content-and-format-q03", "text": "What may an agent decide or do once the content of a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "access-and-rights", "name": "Access, rights and retention", "description": "Who may read, copy or change it, and for how long it is kept.", "findings": [ { "id": "access-rules", "name": "Access rules and retention", "description": "The permissions attached to a systemic lupus erythematosus and the period it survives.", "questions": [ { "id": "access-rules-q01", "text": "What identifies and describes access to a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "access-rules-q02", "text": "Who or what asserted this about access to a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "access-rules-q03", "text": "What may an agent decide or do once access to a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "subject-and-method", "name": "Subject matter and method", "description": "What systemic lupus erythematosus studies and how it establishes anything.", "rationale": "A field is identified by its questions and its methods, and those are what distinguish it from the fields next to it.", "layers": [ { "id": "subject", "name": "Subject matter", "description": "The questions it takes as its own.", "findings": [ { "id": "subject-record", "name": "Questions and objects of study", "description": "What it is about, stated so a neighbouring field can be told apart.", "questions": [ { "id": "subject-record-q01", "text": "What questions and objects does systemic lupus erythematosus take as its own?", "kind": "definition" }, { "id": "subject-record-q02", "text": "Which questions does it share with a neighbouring field, and who claims them?", "kind": "boundary" } ] } ] }, { "id": "method", "name": "Method and evidence", "description": "How claims are established and what counts as evidence.", "findings": [ { "id": "method-record", "name": "Methods and standards of evidence", "description": "The methods used and what they are taken to establish.", "questions": [ { "id": "method-record-q01", "text": "By what methods does systemic lupus erythematosus establish claims, and what counts as sufficient evidence?", "kind": "provenance" }, { "id": "method-record-q02", "text": "What kind of claim can this field not settle, and where should an agent look instead?", "kind": "action" } ] } ] } ] }, { "id": "institutions-and-classification", "name": "Institutions and classification", "description": "Where systemic lupus erythematosus is practised and how catalogues place it.", "rationale": "The institutional footprint is the evidence that a field exists as a field rather than as a topic.", "layers": [ { "id": "institutions", "name": "Institutional markers", "description": "Societies, journals, degrees and departments.", "findings": [ { "id": "institution-record", "name": "Bodies and venues", "description": "Where the field organises itself.", "questions": [ { "id": "institution-record-q01", "text": "Which societies, journals or degrees mark systemic lupus erythematosus as an established field?", "kind": "provenance" }, { "id": "institution-record-q02", "text": "What would show that it is emerging or dissolving rather than established?", "kind": "boundary" } ] } ] }, { "id": "classification", "name": "Classification schemes", "description": "Where library and research classifications put it.", "findings": [ { "id": "classification-record", "name": "Codes and their disagreements", "description": "The classification codes that place it, and where they differ.", "questions": [ { "id": "classification-record-q01", "text": "Which classification schemes place systemic lupus erythematosus, under what codes?", "kind": "definition" }, { "id": "classification-record-q02", "text": "Where do those schemes disagree about its scope?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a systemic lupus erythematosus came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a systemic lupus erythematosus and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a systemic lupus erythematosus is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a systemic lupus erythematosus, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a systemic lupus erythematosus, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a systemic lupus erythematosus is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 6, "layers": 12, "findings": 14, "questions": 38 } } } }